Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myeloma X Relapse (Intensive)
2006-005890-24Phase 4Completed
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- Oct 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of melphalan, bortezomib, doxorubicin, dexamethasone, cyclophosphamide and 1 more in multiple myeloma (MM) (2 arms), sponsored by Leeds Teaching Hospitals NHS Trust. Primary endpoint: Freedom from disease progression. Started Oct 2007; status: completed.
02
Drugs
melphalanbortezomibdoxorubicindexamethasonecyclophosphamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2006-005890-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005890-24.